Mary Eileen Dolan to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Mary Eileen Dolan has written about Dose-Response Relationship, Drug.
Connection Strength
0.522
-
Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities. Clin Cancer Res. 2019 02 15; 25(4):1147-1155.
Score: 0.123
-
Whole-genome approach implicates CD44 in cellular resistance to carboplatin. Hum Genomics. 2009 Jan; 3(2):128-42.
Score: 0.063
-
Role of GADD34 in modulation of cisplatin cytotoxicity. Biochem Pharmacol. 2006 Jan 12; 71(3):239-47.
Score: 0.051
-
Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities. J Pharmacol Exp Ther. 2005 Dec; 315(3):1247-55.
Score: 0.050
-
Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors. Clin Cancer Res. 2002 Aug; 8(8):2519-23.
Score: 0.040
-
Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells. Clin Cancer Res. 2002 Aug; 8(8):2696-700.
Score: 0.040
-
Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patients. Clin Cancer Res. 2000 Oct; 6(10):3870-7.
Score: 0.035
-
Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and analogues in nonhuman primates. Clin Cancer Res. 2000 Sep; 6(9):3662-9.
Score: 0.035
-
Effects of polyamine analogues on prostatic adenocarcinoma cells in vitro and in vivo. Cancer Chemother Pharmacol. 1998; 41(6):505-12.
Score: 0.029
-
Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. Cancer Commun. 1990; 2(11):371-7.
Score: 0.017
-
Depletion of O6-alkylguanine-DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by treatment with O6-methylguanine. Cancer Chemother Pharmacol. 1989; 25(2):103-8.
Score: 0.016
-
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol. 2002 May 01; 20(9):2277-83.
Score: 0.010
-
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res. 2000 Aug; 6(8):3025-31.
Score: 0.009
-
Prolonged depletion of O6-methylguanine DNA methyltransferase activity following exposure to O6-benzylguanine with or without streptozotocin enhances 1,3-bis(2-chloroethyl)-1-nitrosourea sensitivity in vitro. Cancer Res. 1993 Sep 15; 53(18):4281-6.
Score: 0.005